Qure.ai
FDA-cleared AI radiology platform detecting TB, stroke, lung cancer and fractures across 105+ countries
Overview
Qure.ai is a Mumbai-based medical AI company founded in 2016 that builds deep-learning algorithms for automated interpretation of chest X-rays, head CTs, lung CTs, and musculoskeletal X-rays. Its flagship product qXR detects up to 30+ chest findings including tuberculosis, pneumonia, lung nodules, and COVID-19, while qER triages intracranial haemorrhage and stroke from head CTs and qMSK identifies fractures across 15 bone anatomies. As of mid-2026 the platform is deployed at 5,500+ sites across 105+ countries, has impacted an estimated 45 million lives, holds 26 FDA-cleared indications across 9 products, and is cited twice in WHO TB screening guidelines — making it the world's most widely deployed healthcare AI by site count.
Beyond individual diagnostic tools, Qure.ai operates qTrack, a disease management platform for TB care cascades, and Aira, a multi-disease clinical AI co-pilot. In January 2026 the Bill and Melinda Gates Foundation awarded the company a multimillion-dollar grant to develop AI-powered point-of-care ultrasound (POCUS) for TB and pneumonia detection in low-resource settings, alongside an open-source multimodal lung health database. The company raised a $65 million Series D in September 2024 led by Lightspeed and 360 ONE Asset, bringing total funding to approximately $141 million, and was named to TIME's 100 Most Influential Companies of 2025.
Pricing
Pricing shown for reference only. These figures reflect RECATOOLS research as of 16 Jun 2026 and may be out of date or incomplete. This is not financial or purchasing advice — always confirm the current price on the provider’s official website before making any decision.
Use cases
What you can produce with Qure.ai
- Automated chest X-ray report flagging up to 30 abnormalities with bounding-box overlays, ready for radiologist review within seconds
- Prioritised worklist for head CT scans with suspected intracranial bleeds, mass effect, or cranial fractures, enabling faster treatment decisions
- Lung nodule volumetric measurements and risk stratification output compatible with Lung-RADS classification for oncology handoff
- Fracture detection annotations on trauma MSK X-rays across 15 anatomies, processed in under a minute per scan
- TB patient tracking dashboard via qTrack showing screening outcomes, GeneXpert referral rates, and treatment initiation across a programme cohort
- PACS-integrated DICOM output overlays that route into existing radiology information systems without requiring separate viewer installation
- Regulatory-ready audit logs and performance dashboards for site-level quality monitoring and compliance reporting
ASEAN Perspective
Qure.ai in Southeast Asia
Qure.ai has significant ASEAN footprint anchored by tuberculosis control programmes: qXR is actively deployed in the Philippines (partnership with PBSP and Siemens Healthineers for mobile X-ray TB screening in high-burden cities) and has been used in Vietnam as part of the "Double X" strategy combining AI chest X-ray with GeneXpert, screening over 96,000 participants between 2020 and 2022. The platform holds regulatory approvals in ASEAN nations and is referenced in Southeast Asian public-health programmes supported by USAID and the Stop TB Partnership. For APAC enterprise buyers the data-residency question is material: Qure.ai supports on-premise deployment of its models (confirmed for qMSK and stated for cloud-or-on-premise options across products), which can satisfy data localisation requirements in markets such as Indonesia (PDPl) and Thailand (PDPA), though buyers should contractually confirm where training data and inference logs are processed. The January 2026 Gates Foundation POCUS grant explicitly names sub-Saharan Africa and Southeast Asia as priority regions, signalling continued investment in the region.
Qure.ai is one of the most credentialled and widely deployed AI radiology platforms in the world, with a regulatory portfolio (26 FDA-cleared indications, Class IIb CE under EU MDR, CDSCO Class B in India, registrations in 85+ countries) that few competitors match. Its core products — qXR for chest pathology and qER for head CT triage — have been validated in peer-reviewed studies including publications in The Lancet, and the WHO has twice cited qXR in its official TB screening guidelines. For healthcare systems in lower-resource environments the cost-effectiveness argument is well-documented: independent evaluations in India show measurable increases in TB detection rates alongside reduced per-case diagnostic costs.
The main caveats are practical: pricing is fully opaque and negotiated on enterprise terms, which makes budget planning difficult for smaller hospital systems or NGOs without procurement support. Integration depth varies by site — Qure.ai connects via DICOM and PACS but implementation timelines and on-premise deployment complexity depend heavily on the local IT environment. The product portfolio covers radiology and emerging POCUS, but does not yet extend to pathology slides, endoscopy, or other imaging modalities competitors are pursuing. For organisations already operating within Qure.ai's disease focus areas (TB, lung cancer, stroke, trauma), the clinical evidence and global support network represent a compelling proposition; for others, the narrower scope is a limitation to weigh.
What people say
Qure.ai lacks sufficient G2 or Capterra reviews to cite aggregate scores, reflecting an enterprise sales model where procurement bypasses consumer review platforms. Qualitative feedback from published clinical studies and NGO programme reports is consistently positive on detection accuracy (qXR tuberculosis sensitivity validated at WHO benchmark levels) and workflow integration. Independent peer-reviewed assessments, including in The Lancet and Scientific Reports, support the accuracy claims. Buyers consistently flag opaque pricing and implementation complexity as friction points, while clinical staff in low-resource deployments highlight the speed advantage — pre-read in seconds versus multi-day waits — as transformative for high-burden disease programmes.
Summary of public user & expert reviews, compiled by RECATOOLS.
Notable facts
- Qure.ai holds 26 FDA-cleared indications across 9 products — more FDA clearances for lung cancer AI than any other company in the US as of 2025.
- The company's qXR chest X-ray AI is cited twice in the WHO's official TB screening guidelines, giving it quasi-official status in global public health programmes.
- TIME Magazine named Qure.ai to its 100 Most Influential Companies of 2025 list in the Pioneer category, alongside pharmaceutical giants like Gilead and Vertex.
- In January 2026 the Bill and Melinda Gates Foundation awarded Qure.ai a multimillion-dollar grant to build AI-powered point-of-care ultrasound, with plans to release a large open-source multimodal lung health database as part of the project.
Frequently asked questions
About this listing
This entry was compiled from publicly available data including Qure.ai's official website, press releases, documentation, and reputable third-party publications. RECATOOLS is not affiliated with Qure.ai unless explicitly stated.
Third-party AI tools update their pricing, features, availability, and policies frequently. Information here may be outdated by the time you read this — we make reasonable efforts to keep listings current, but cannot guarantee absolute accuracy.
For the latest details, please refer to Qure.ai directly →
Spotted something out of date? Suggest an update →
Alternatives to Qure.ai
More in Other
